亚太药业
(002370)
| 流通市值：34.60亿 | | | 总市值：34.60亿 |
| 流通股本：7.46亿 | | | 总股本：7.46亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 218,379,523.9 | 157,522,506.43 | 59,576,342.35 | 323,136,959.51 |
| 营业收入 | 218,379,523.9 | 157,522,506.43 | 59,576,342.35 | 323,136,959.51 |
| 二、营业总成本 | 228,396,660.62 | 151,041,056.27 | 61,867,871.14 | 368,315,692.88 |
| 营业成本 | 148,157,428.79 | 103,535,620.23 | 38,399,298.48 | 216,139,876.06 |
| 税金及附加 | 3,369,911.66 | 2,101,206.52 | 1,120,727.85 | 5,578,936.66 |
| 销售费用 | 27,744,747.64 | 19,597,050.81 | 10,757,854.98 | 52,548,016.64 |
| 管理费用 | 43,066,001.81 | 22,827,836.27 | 10,213,330.03 | 52,562,158.12 |
| 研发费用 | 11,046,395.36 | 6,380,034.95 | 3,291,867.82 | 15,467,732.77 |
| 财务费用 | -4,987,824.64 | -3,400,692.51 | -1,915,208.02 | 26,018,972.63 |
| 其中:利息费用 | 65,419.44 | - | - | 34,704,751.21 |
| 其中:利息收入 | 5,073,718 | 3,408,138.08 | 1,919,083.47 | 8,738,770.8 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -9,182,686.77 | -7,119,515.01 | -1,704,336.58 | 830,085.38 |
| 加:投资收益 | 6,058,116.41 | 1,117,584.39 | 101,716.15 | 150,238,962.52 |
| 资产处置收益 | - | - | - | -57,942.49 |
| 资产减值损失(新) | -3,040,255 | -3,040,255 | -2,368,761.17 | -23,103,284.03 |
| 信用减值损失(新) | -4,499,724.53 | -3,053,709.02 | -271,742.87 | 858,982.13 |
| 其他收益 | 4,509,482.98 | 4,226,169.64 | 3,738,236.85 | 6,920,283.12 |
| 四、营业利润 | -16,172,203.63 | -1,388,274.84 | -2,796,416.41 | 90,508,353.26 |
| 加:营业外收入 | 928,696.57 | 474,409.8 | 3,592.8 | 7,200,776.15 |
| 减:营业外支出 | 827,937.66 | 100,708.98 | 50,356.59 | 1,276,788.95 |
| 五、利润总额 | -16,071,444.72 | -1,014,574.02 | -2,843,180.2 | 96,432,340.46 |
| 减:所得税费用 | -690,012.06 | -498,227.26 | -255,650.49 | 124,512.81 |
| 六、净利润 | -15,381,432.66 | -516,346.76 | -2,587,529.71 | 96,307,827.65 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -15,381,432.66 | -516,346.76 | -2,587,529.71 | 96,307,827.65 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -14,252,457.66 | -435,474.46 | -2,587,529.71 | 96,307,827.65 |
| 少数股东损益 | -1,128,975 | -80,872.3 | - | - |
| 扣除非经常损益后的净利润 | -15,183,437.88 | 1,395,412.98 | -4,368,585.08 | -64,687,770.15 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | 0 | 0 | 0.13 |
| (二)稀释每股收益 | -0.02 | 0 | 0 | 0.13 |
| 九、综合收益总额 | -15,381,432.66 | -516,346.76 | -2,587,529.71 | 96,307,827.65 |
| 归属于母公司股东的综合收益总额 | -14,252,457.66 | -435,474.46 | -2,587,529.71 | 96,307,827.65 |
| 归属于少数股东的综合收益总额 | -1,128,975 | -80,872.3 | - | - |
| 公告日期 | 2026-10-26 | 2026-08-26 | 2026-04-25 | 2026-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |